Herein, we report the final survival outcomes.<h4>Methods</h4>This multicenter, single-arm, phase II trial enrolled patients with histologically proven, HER2-negative or unknown gastric cancer with para-aortic (no.16a2/16b1) and/or bulky lymph node metastases. The gene discussed is ERBB2; the disease is gastric cancer.